Depression Treatment in Maplewood, NJ

Depression is not sadness. It is a medical condition with observable symptoms — low mood that lasts most of the day nearly every day for at least two weeks, loss of interest in things you used to care about, changes in appetite and sleep, cognitive slowing, worthless thinking, and in some cases suicidal thoughts. The DSM-5-TR codifies nine criteria, of which five (including one of the first two) are required for a major depressive episode diagnosis. That structural definition matters because it separates depression from the normal difficulty of a hard season in life.

Roughly 1 in 10 US adults experience a major depressive episode in any given year¹, and depression often runs longer and feels heavier than people expect. It is treatable. Most patients respond to a combination of medication and psychotherapy within 6–12 weeks, and most achieve sustained remission with the right plan. The barrier to good outcomes is rarely whether depression responds to treatment — it usually does — but whether the treatment was actually matched to the patient, adjusted promptly, and sustained long enough.

This page is the long-form version of what an initial depression visit covers at our Maplewood office and over NJ-wide telehealth: what depression is and isn't, which medications are first-line and why, what the evidence says about therapy alongside medication, what to do when the first medication doesn't work, how long treatment lasts, how to stop safely, and the specific forms of depression (postpartum, seasonal, perimenopausal, treatment-resistant) that need slightly different plans.

Depression diagnosis runs through three checks. The first is the clinical interview — a structured conversation that maps your symptoms against the DSM-5-TR nine criteria for a major depressive episode. The second is the PHQ-9, a validated nine-item self-report screener that produces a severity score (0–27, with 10+ suggesting a probable episode and 20+ suggesting severe depression). The PHQ-9 is not a diagnosis on its own — the clinical interview is — but it anchors the conversation in shared data and gives us a baseline to measure treatment response from at future visits.

The third check is ruling out medical conditions that cause depression-like symptoms. Thyroid disease — especially hypothyroidism — mimics depression almost exactly; a TSH and free T4 panel catches it. Vitamin B12 deficiency produces fatigue, cognitive slowing, and low mood and can be corrected with supplementation alone. Iron-deficiency anemia causes the same fatigue-and-apathy pattern. Sleep apnea produces daytime fog, irritability, and low motivation that looks like depression. Certain medications — corticosteroids, beta-blockers, interferon, some hormonal contraceptives — can produce depressive symptoms as side effects. We screen for each at the initial visit and order labs when the history warrants it.

The C-SSRS (Columbia Suicide Severity Rating Scale) is embedded in every depression intake. Depression contributes to disability, lost work, family strain, and — at its most severe — suicide. The cost is real even when the depression is treatable. We ask explicitly, structurally, and without euphemism, because asking does not introduce the idea — it identifies people who need a safety plan.

The APA's depression guideline recognizes seven psychotherapies with first-line evidence: Cognitive Therapy (CT), Cognitive Behavioral Therapy (CBT), Behavioral Therapy (BT), Interpersonal Psychotherapy (IPT), Mindfulness-Based Cognitive Therapy (MBCT), Psychodynamic Therapy, and Supportive Therapy. All of them outperform waitlist controls; the best evidence base is for CBT and IPT. The right fit depends on what you actually respond to in a therapeutic relationship, not on which acronym is trending.

Teresa provides brief supportive therapy and motivational interviewing during medication visits — that is within PMHNP scope and is where a lot of the real work of staying on a plan actually happens. For structured weekly CBT, IPT, or MBCT with a dedicated therapist, we refer to New Jersey-based licensed clinical social workers and psychologists we trust and coordinate with. Many patients benefit from the split-treatment model: medication with Teresa every 4–8 weeks plus weekly therapy with someone whose full hour is devoted to it. Both clinicians share notes with your written consent so nobody is working blind.

Mindfulness-Based Cognitive Therapy is worth naming specifically because it has the strongest evidence base for preventing recurrence in patients with three or more prior depressive episodes. It blends cognitive techniques with an eight-week mindfulness curriculum. MBCT is under-recommended in mainstream psychiatry and under-prescribed even when it's the best-fit option; we mention it when the history suggests recurrent-depression pattern because the recurrence-reduction data is meaningful.

Depression treatment runs in three phases. The acute phase is the first 6–12 weeks during which we are working to get you into remission — meaning a PHQ-9 score below 5 and a return to near-baseline functioning. Most SSRIs take 2–4 weeks to produce noticeable benefit and 6–8 weeks at an adequate dose before we call a trial inadequate. Expect more frequent visits during this phase — every 2 weeks until we see response, then every 4 weeks.

The continuation phaseruns from about week 12 through month 6–9 after remission. The goal is to prevent relapse of the current episode — the episode is not “over” until you've been symptom-free for several months on medication. Visits typically move to every 6–8 weeks. Stopping medication during the continuation phase produces an approximately 50% relapse rate; staying the course cuts that in half.

The maintenance phaseapplies to patients with recurrent depression — two or more prior episodes, severe or suicidal episodes, or a first episode in a patient with strong family history. For these patients, ongoing treatment beyond nine months significantly reduces recurrence. For patients with a single, moderate first episode, a supervised taper at 9–12 months of stable remission is appropriate. We re-evaluate the phase you're in at each visit and adjust the plan.

Depression during pregnancy (prenatal depression) and in the year after delivery (postpartum depression) is common — roughly 1 in 8 mothers³ — and is systematically under-treated because patients and clinicians both hesitate around medication during pregnancy. The honest framing is that untreated perinatal depression has documented risks to the pregnancy (preterm birth, low birthweight, worse neonatal outcomes) and to maternal safety (suicide remains a leading cause of maternal mortality). Those risks have to be weighed against the risks of specific medications, which for most SSRIs are lower than the risks of untreated depression.

Sertraline and escitalopram are the most commonly used SSRIs in pregnancy and lactation, with the largest reassuring safety datasets. Paroxetine is generally avoided during the first trimester due to a small increase in cardiac malformation risk. Bupropion is also commonly continued. Benzodiazepines carry more risk and are used sparingly. For patients who were already on an antidepressant when they conceived, abruptly stopping to “protect the baby” is often the wrong call — relapse risk is high and the medication switch itself exposes the fetus to a transition period. Continuing a medication that is working is frequently the better plan.

Zuranolone (Zurzuvae) is an FDA-approved oral medication specifically for postpartum depression, taken once daily for 14 days. It has a rapid-onset response, which is meaningful in a population where every week of illness affects the baby's attachment and the mother's recovery. We discuss it when the clinical picture fits. For mothers who prefer to start with non-pharmacologic treatment, interpersonal psychotherapy has strong evidence for postpartum depression specifically and we make referrals accordingly.

Some complementary approaches have good evidence and are worth incorporating alongside medication and therapy. Aerobic exercise at moderate intensity 3–5 times per week produces an antidepressant effect with an effect size comparable to SSRIs for mild-to-moderate depression; the mechanism is likely multifactorial (BDNF, inflammation, sleep architecture). Omega-3 fatty acids (EPA-predominant formulations at 1–2 g/day) have modest evidence as adjunctive treatment. A Mediterranean-pattern diet correlates with lower depression prevalence and may have causal benefit.

Some popular options have weaker evidence than their reputation suggests. St. John's Wort has small-study evidence for mild depression but interacts with many prescription medications (including SSRIs, birth control, warfarin, and immunosuppressants) and is not recommended for moderate-to-severe depression. SAMe and 5-HTP have mixed evidence and inconsistent supplement purity. Acupuncture has equivocal data for depression. We discuss any of these honestly when patients bring them up — the goal is not to dismiss what you're already doing but to tell you what the evidence actually supports.

Sleep hygiene is where the biggest leverage often hides. Depression disrupts sleep and poor sleep worsens depression in a loop that medication alone rarely breaks. Consistent sleep and wake times, morning light exposure, limiting caffeine after noon, and restricting bed use to sleep and intimacy are the basic interventions. For patients with persistent insomnia, CBT-I (cognitive behavioral therapy for insomnia) has better long-term outcomes than sleep medications and we refer for it when indicated.